[an error occurred while processing this directive] ����Ƥ���Բ�ѧ��־ 2009, 35(6) 359-360 DOI:     ISSN: 2096-5540 CN: 32-1880/R

����Ŀ¼ | ����Ŀ¼ | ������� | �߼�����                                                            [��ӡ��ҳ]   [�ر�]
����
��չ����
������Ϣ
Supporting info
PDFȫ��
[HTMLȫ��]
�����
�����뷴��
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
����
Email Alert
���·���
���������Ϣ
���Ĺؼ����������
��Ƥ�ʼ�����
Ͷҩ���ֲ�
����
���������������
�ǽ���
����
PubMed
Article by Qiao,J.J
Article by Fang,h

��ȷ������Ƥ�ʼ���

�ǽ���,����

�㽭��ѧҽѧԺ������һҽԺƤ����

ժҪ��

������Ƥ�ʼ��������ƺܶ�Ƥ��������Ҫ����֮һ�����ʹ�õõ�����ȫ��Ч��������Ӧͨ����С��������߰Ѳ�ͬЧ����������Ƥ�ʼ�������������ֵ�ǿ��������Ƥ�ʼ��صIJ�����Ӧ���������ϵͳӦ����Ƥ�ʼ��صIJ�����Ӧ��ͬ������������ٴ�����ҩ�����㣬��Ч�����롣Ӣ��Ƥ����ѧר�Ҿ�������Ƥ�ʼ��ص�ʹ�ô�ɹ�ʶ����ϸù�ʶ��������ȷʹ��������Ƥ�ʼ��صķ����������Ը���ҩ��Ŀ־�С�

�ؼ����� ��Ƥ�ʼ�����   Ͷҩ���ֲ�   ����  

Rational use of topical corticosteroids

Abstract:

Topical corticosteroids are an important treatment modality for dermatoses. If used correctly, they are effective and safe with insignificant side effects. However, some patients overemphasize the side effects of topical steroids, confuse topical steroids of various potency, and equalize their side effects with those of systemic steroids, which may lead to insufficient application of steroids and unsatisfactory efficacy. A working group of dermatology experts in the United Kingdom have reached a consensus on the application of topical corticosteroids. This article describes the principles for correct application of topical corticosteroids according to the consensus, so as to eliminate the fear for topical corticosteroids.

Keywords: Glucocorticosteroids   Administration��topical   Methods  
�ո����� 2009-05-19 �޻����� 2009-06-24 ����淢������ 2009-11-13 
DOI:
������Ŀ:

ͨѶ����: �ǽ���
���߼��:

�ο����ף�
[1]     Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54(1): 1-15.
[2]     Bewley A. Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids. Br J Dermatol 2008; 158(5): 917-920.
[3]     Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142(5): 931-936.
[4]     Long CC, Finlay AY. The finger-tip unit--a new practical measure. Clin Exp Dermatol 1991; 16(6): 444-447.
[5]     Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. Clin Exp Dermatol 2003; 28(5): 549-553.
[6]     Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007; 156(2): 203-221.
[7]     Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147(3): 528-537.
[8]     Luger TA, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004; 15(3): 169-178.
�������������
1��������, �Ź���.�����Χ�񾭹����𺦼������[J]. ����Ƥ���Բ�ѧ��־, 0,(): 265-267
2��������, ��Ϊ��.��Ƥ�ʼ�����Ƥ�׵��о���չ[J]. ����Ƥ���Բ�ѧ��־, 0,(): 268-270
3�����̷�, ����.��Ƥ�ʼ������Ƶֿ����Ƶ��о���չ[J]. ����Ƥ���Բ�ѧ��־, 2004,30(6): 345-347
4��������, �Ź���.�����Χ�񾭹����𺦼������[J]. ����Ƥ���Բ�ѧ��־, 0,(): 265-267
5��������, ��Ϊ��.��Ƥ�ʼ�����Ƥ�׵��о���չ[J]. ����Ƥ���Բ�ѧ��־, 0,(): 268-270
6����ϲƽ, ����ǿ, �����.SLE����оƬ������о���չ[J]. ����Ƥ���Բ�ѧ��־, 2006,32(6): 346-348
7��������, �Ź���.�����Χ�񾭹����𺦼������[J]. ����Ƥ���Բ�ѧ��־, 2005,31(5): 265-267
8��������, ��Ϊ��.��Ƥ�ʼ�����Ƥ�׵��о���չ[J]. ����Ƥ���Բ�ѧ��־, 2005,31(5): 268-270
9����ѩӢ �ǽ���.IgG4����Լ������о���չ[J]. ����Ƥ���Բ�ѧ��־, 2016,42(1): 23-25

�������� (��ע��:��վʵ�������Ը�, �벻Ҫ������ѧ���޹ص�����!�������ݲ�����վ�۵�.)

Copyright 2008 by ����Ƥ���Բ�ѧ��־